WELCOME TO THE HYLORIS INVESTOR RELATIONS PAGE

Innovation for a healthier tomorrow

Shareholder information

Investor presentation

VIEW
Share stock price

Shareholder information

VIEW MORE
Financial information

Financial reports

View more

Press Releases

27.07.21 Hyloris to Report 2021 Half-Year Results on 4 August 2021
EN
FR
08.07.21 Hyloris Announces Launch of Maxigesic®IV, a Novel Non-Opioid Pain Treatment, in Key European Markets
EN
FR
24.06.21 Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group
EN
FR
08.06.21 Hyloris Shareholders Unanimously Approve all Resolutions at 2021 Annual General Meeting
EN
FR
07.05.21 Hyloris Announces Annual General Meeting of Shareholders on 8 June 2021
EN
FR
06.05.21 Hyloris Announces Extension of Footprint of Maxigesic® IV into South America
EN
FR
28.04.21 Hyloris Announces Major Commercial Partnership in the U.S. for Maxigesic® IV
EN
FR
08.04.21 Hyloris Announces Further Extension of European Footprint of Maxigesic®IV
EN
FR
09.03.21 Hyloris Reports Full Year 2020 Financial Results
EN
FR
05.03.21 Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets
EN
FR
03.03.21 Hyloris to Report its Full Year 2020 Results on 9 March 2021
EN
FR
VIEW ALL PRESS RELEASES
What Hyloris does
Hyloris Pharmaceuticals Investors
Contact us